by Jason Heaviland | Nov 24, 2025 | Uncategorized
How Metabolomic Biomarkers Could Save PRMT5 Drug Development The PRMT5 inhibitor field represents one of the most expensive lessons in modern oncology drug development. Despite massive investments – including Bristol Myers Squibb’s $4.8 billion acquisition...
by Jason Heaviland | Nov 24, 2025 | Uncategorized
Linking Protein Degradation to Functional Metabolic Consequences Molecular glue degraders induce targeted protein degradation through E3 ligase modulation, but measuring protein loss alone provides an incomplete picture of therapeutic activity. The functional...
by Jason Heaviland | Nov 24, 2025 | Uncategorized
Biomarker-Driven mRNA Trials: How Discovery Metabolomics Finds the Responders Before Treatment Your Phase 2 mRNA therapeutic trial enrolled sixty patients. Twenty showed remarkable responses. Thirty had modest benefits. Ten showed no response at all. Now you’re...
by Jason Heaviland | Nov 24, 2025 | Uncategorized
Two Targets, One Pathway: The Metabolomic Logic Behind MAT2A/PRMT5 Combination Therapies The next breakthrough in cancer treatment may come from attacking two targets within the same metabolic pathway. MAT2A and PRMT5 inhibitor combinations represent a new paradigm in...
by Jason Heaviland | Nov 21, 2025
Unlocking FFPE Archives: How TissueBridge™️ Enables Retrospective Profiling of Tumor Metabolism Panome Bio’s TissueBridge technology unlocks the full metabolomic potential of FFPE tissue archives, enabling comprehensive, high-confidence profiling of tumor metabolism...
